

## LISTING OF CLAIMS

1. (Currently Amended) A method for producing an allograft cell designed to inhibit development of an adaptive T cell response, the method specifically inhibiting the development of an adaptive T cell response to target cell-specific, cell surface-expressed alloantigens comprising:

providing ~~contacting *ex vivo* a target cell expressing said alloantigen with an a~~ non-immunogenic expression vector encoding a CD8 polypeptide consisting of all or a functional portion of a CD8  $\alpha$ -chain, wherein said CD8  $\alpha$ -chain includes a transmembrane domain for expression of said CD8  $\alpha$ -chain on the surface of said target cell whereby said CD8  $\alpha$ -chain inhibits the development of adaptive T cell immunity to the cell surface-expressed alloantigens ~~upon transplantation; and~~

contacting *ex vivo* an allograft cell expressing a surface alloantigen with the non-immunogenic expression vector.

2-4. (Cancelled)

5. (Currently Amended) A method for specifically inhibiting the development of an adaptive T cell responses to donor cell surface-expressed alloantigens in a recipient, comprising:

(a) contacting *ex vivo* donor allograft cells expressing said donor alloantigens with ~~an a~~ a non-immunogenic expression vector encoding a CD8 polypeptide consisting of all or a functional portion of a CD8  $\alpha$ -chain prior to or contemporaneous with transplantation of said allograft cells into said recipient, wherein said CD8  $\alpha$ -chain includes a transmembrane domain for expression of said CD8  $\alpha$ -chain on the surface of said donor allograft cells;

(b) transplanting said donor allograft cells into said recipient, wherein said cell surface expression of said CD8  $\alpha$ -chain by said allograft cells specifically inhibits the development an adaptive T cell responses to said donor alloantigens.

6. (Currently Amended) A method for extending the survival of an allograft in a recipient, comprising:

(a) contacting *ex vivo* cells of said allograft with ~~an~~ a non-immunogenic expression vector encoding a CD8 polypeptide consisting of all or a functional portion of a CD8  $\alpha$ -chain prior to or contemporaneous with transplantation of said allograft into said recipient, wherein said CD8  $\alpha$ -chain includes a transmembrane domain for expression of said CD8  $\alpha$ -chain on the surface of said donor allograft cells;

(b) transplanting said allograft into said recipient, wherein said cell surface expression of said CD8  $\alpha$ -chain extends the survival time of said allograft.

7-13. (Cancelled)

14. (Previously Presented) The method according to any one of Claims 1, 5, and 6, wherein said CD8  $\alpha$ -chain is a human CD8  $\alpha$ -chain.

15. (Previously Presented) The method according to any one of Claims 1, 5, and 6, wherein said CD8  $\alpha$ -chain consists of a CD8  $\alpha$ -chain extracellular domain and a transmembrane domain.

16. (Cancelled)

17. (Previously Presented) The method according to Claim 15 wherein said transmembrane domain is a CD8  $\alpha$ -chain transmembrane domain.

18. (Withdrawn) An improved transplant allograft comprising allograft cells modified to express a CD8 polypeptide comprising the CD8  $\alpha$ -chain, wherein said allograft is capable of effectively and specifically inhibiting a recipient immune response to alloantigens.

19. (Withdrawn) The improved transplant allograft of Claim 18, wherein modification of said allograft cells is achieved using viral-mediated delivery of a nucleic acid encoding said CD8 polypeptide.
20. (Withdrawn) The improved transplant allograft according to Claims 18 or 19, wherein said CD8 polypeptide is a human CD8 polypeptide.
21. (Withdrawn) An improved organ preservation solution comprising a vector comprising a nucleic acid encoding a CD8 polypeptide, said CD8 polypeptide comprising a CD8  $\alpha$ -chain.
22. (Withdrawn) The improved organ preservation solution according to Claim 21, wherein said CD8 polypeptide is a human CD8 polypeptide.
23. (Withdrawn) The improved organ preservation solution according to Claim 21 or 22, wherein said CD8 polypeptide consists essentially of the extracellular domain of the CD8  $\alpha$ -chain and a transmembrane domain.
24. (Withdrawn) The improved organ preservation solution according to any one of Claims 21 to 23, wherein said transmembrane domain is the CD8 $\alpha$ -chain transmembrane domain.
25. (Withdrawn) The improved organ preservation solution according to Claim 21, wherein said nucleic acid encoding said CD8 polypeptide comprises the sequence set forth in (SEQ ID NOS:27-28).
26. (Withdrawn) The improved organ preservation solution according to Claim 21, wherein said CD8 polypeptide consists essentially of the sequence as set forth in (SEQ ID NOS:27-28).

27-39. (Cancelled)